Trial Profile
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Lorigerlimab (Primary)
- Indications Carcinoma; Colorectal cancer; Fallopian tube cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Skin cancer; Solid tumours; Squamous cell cancer; Thymoma
- Focus Adverse reactions; First in man
- Sponsors MacroGenics
- 13 Feb 2024 Planned End Date changed from 1 Sep 2024 to 1 Dec 2024.
- 13 Feb 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Jul 2024.
- 07 Nov 2023 Planned End Date changed from 1 Apr 2024 to 1 Sep 2024.